Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR) announced a proposed underwritten public offering of $75 million of common stock and, optionally for some investors, pre-funded warrants, with a 30-day option for underwriters to purchase up to an additional $11.25 million.
Proceeds are intended to fund development of nomlabofusp and for working capital and general corporate purposes. The offering is subject to market conditions; final terms will be in a prospectus supplement filed with the SEC.
Positive
- $75 million capital raise announced to fund operations
- Up to $86.25 million potential proceeds including underwriter option
- Proceeds earmarked for nomlabofusp development and R&D
Negative
- Offering will dilute existing shareholders if completed
- Completion is uncertain and subject to market conditions
News Market Reaction – LRMR
In the Feb 26 session, LRMR declined 7.23%, reflecting a notable negative market reaction. Argus tracked a peak move of +81.1% during that session. Our momentum scanner triggered 131 alerts that day, indicating very high trading interest and price volatility. Trading volume was exceptionally heavy at 14.4x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 31 | Offering closed | Positive | -0.6% | Closing of underwritten offering with full over-allotment exercise and $69M gross proceeds. |
| Jul 29 | Offering priced | Positive | +1.1% | Pricing of 18.75M-share underwritten offering at $3.20 with 30-day option. |
| Jul 29 | Offering proposed | Neutral | +1.1% | Announcement of proposed common stock and pre-funded warrant offering under S-3. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior offerings around nomlabofusp funding produced modest average moves (~0.56%), with one negative reaction on closing but generally limited volatility versus the headlines’ importance.
Over the past year, Larimar used equity offerings to fund development of nomlabofusp while advancing toward regulatory milestones. In July 2025, it proposed and then priced an underwritten public offering at $3.20 per share, targeting up to $69.0M in gross proceeds, followed by a closing announcement that included full exercise of the underwriters’ option. These financings were earmarked for nomlabofusp and broader pipeline work, similar to today’s proposed $75M raise focused on the same lead asset and general corporate needs.
Key Terms
underwritten public offering financial
pre-funded warrants financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
securities and exchange commission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of
J.P. Morgan and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.
Larimar intends to use the net proceeds from the proposed offering to support the development of nomlabofusp and for working capital and general corporate purposes, including research and development expenses and commercialization expenses.
The proposed offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-279275) that was declared effective by the Securities and Exchange Commission (“SEC”) on May 24, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may be obtained, when available, from J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of Larimar’s management. Such forward-looking statements include, without limitation, market conditions, statements relating to the completion, timing, size, use of proceeds from the proposed public offering on the anticipated terms or at all and the grant of the option to the underwriters to purchase additional shares of common stock. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the proposed public offering, completion of the proposed public offering on the anticipated terms or at all, and other risks and uncertainties related to the proposed public offering, as well as the risks and uncertainties set forth in the “Risk Factors” section and elsewhere in the preliminary prospectus supplement related to the proposed public offering filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission and available at www.sec.gov, including but not limited to Larimar’s periodic reports, including Larimar’s most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Larimar assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact:
Joyce Allaire
LifeSci Advisors jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
